esomeprazole magnesium
esomeprazole magnesium
Pharmacologic class: Proton pump inhibitor
Therapeutic class: Antiulcer agent
Pregnancy risk category C
Action
Reduces gastric acid production by inhibiting enzyme activity in gastric parietal cells, preventing transport of hydrogen ions into gastric lumen
Availability
Capsules (delayed-release): 20 mg, 40 mg
Powder for delayed-release oral suspension: 2.5-mg, 5-mg, 10-mg, 20-mg, 40-mg packets
Indications and dosages
➣ Treatment of gastroesophageal reflux disease (GERD); healing of erosive esophagitis
Children ages 1 month to younger than 1 year weighing 3 kg (6.5 lb) to 5 kg: 2.5 mg P.O. daily for up to 6 weeks
Adults: 20 to 40 mg P.O. once daily for 4 to 8 weeks
Children ages 1 month to younger than 1 year weighing more than 7.5 kg to 12 kg (16.5 to 26 lb): 10 mg P.O. daily for up to 6 weeks
Children ages 1 month to younger than 1 year weighing more than 5 kg (11 lb) to 7.5 kg: 5 mg P.O. daily for up to 6 weeks
Children ages 1 to 11 weighing 20 kg (44 lb) or more: 10 or 20 mg P.O. daily for 8 weeks
Children ages 1 to 11 weighing less than 20 kg (44 lb): 10 mg P.O. daily for 8 weeks
➣ Treatment of GERD; maintenance of healing of erosive esophagitis
Adults: 20 mg P.O. once daily
➣ Symptomatic GERD
Adults: 20 mg P.O. once daily for 4 weeks
Children ages 12 to 17: 20 or 40 mg P.O. daily for up to 8 weeks
Children ages 1 to 11: 10 mg P.O. daily for up to 8 weeks
➣ Helicobacter pylori eradication to decrease risk of duodenal ulcer recurrence
Adults: 40 mg P.O. once daily for 10 days, given in combination with amoxicillin 1,000 mg b.i.d. for 10 days and with clarithromycin 500 mg b.i.d. for 10 days
➣ Treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome
Adults: 40 mg P.O. b.i.d.
➣ Risk reduction of NSAID-associated gastric ulcer
Adults: 20 or 40 mg P.O. once daily for up to 6 months
Contraindications
• Hypersensitivity to proton pump inhibitors
Precautions
Use cautiously in:
• severe hepatic impairment
• increased risk of hip, wrist, and spine fractures
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).
Administration
• Give 1 hour before or 2 hours after a meal.
• Know that contents of capsules may be mixed with applesauce.
• Don't crush capsules or pellets.
• Be aware that hypomagnesemia has been reported rarely in patients treated with proton pump inhibitors for at least 3 months. For patients expected to be on prolonged treatment or who take proton pump inhibitors with drugs such as digoxin or drugs that may cause hypomagnesemia (such as diuretics), consider monitoring magnesium level before starting treatment.
Adverse reactions
CNS: headache, dizziness, asthenia, vertigo, apathy, anxiety, paresthesia, insomnia, abnormal dreams
EENT: sinusitis, epistaxis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, flatulence, dry mouth
Metabolic: hypomagnesemia
Musculoskeletal: hip, wrist, spine fractures (with long-term daily use)
Respiratory: upper respiratory tract infection, cough
Skin: rash, inflammation, urticaria, pruritus, alopecia, dry skin
Interactions
Drug-drug. CYP2C19 or CYP3A4 inducers (such as rifampin): reduced esomeprazole level
Digoxin, iron salts, ketoconazole: altered absorption and effects of these drugs
Methotrexate: increased serum methotrexate level
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, creatinine, uric acid: increased levels
Hemoglobin, platelets, potassium, sodium, thyroxine, white blood cells: altered levels
Serum chromogranin A (CgA): increased level (may cause falsepositive results in diagnostic investigations for neuroendocrine tumors)
Drug-herbs. St. John's wort: reduced esomeprazole level
Patient monitoring
• Monitor neurologic status, especially for dizziness, headache, paresthesia, and asthenia.
• Watch for signs and symptoms of EENT and respiratory infections.
• Assess nutritional and hydration status in light of adverse GI effects.
• Check for rash and other signs of hypersensitivity.
• Monitor liver function test results if patient is on long-term therapy.
• Continue to monitor patients periodically who are expected to be on prolonged treatment or who take proton pump inhibitors with drugs such as digoxin or drugs that may cause hypomagnesemia.
Patient teaching
• Instruct patient to take drug 1 hour before or 2 hours after a meal.
• If patient has trouble swallowing capsule, tell him to open it, sprinkle pellets into soft food (such as applesauce), and take right away.
• Instruct patient to recognize and report signs or symptoms of hypomagnesemia.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Advise female patient to tell prescriber if she's pregnant or breastfeeding.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.